New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Jessica Merrill
New York, NY
Jessica Merrill is a Bureau Editor for US Commercial Content for Informa’s pharmaceutical news publications, including “The Pink Sheet” and SCRIP. She has been covering the pharmaceutical industry as a journalist for more than 10 years, spanning the spectrum from R&D to regulatory to commercial. She was previously a reporter and editor for “The Pink Sheet” and “Pink Sheet” DAILY, specializing in business and commercial news, focusing largely on big pharma, M&A and business development, and the commercial landscape, including drug launches and market access. Before embarking on a career in healthcare journalism, she covered business news for the cosmetics industry and worked as a newspaper reporter.
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Jessica Merrill
Sanofi CEO Hudson Delivers An Ambitious Turnaround Agenda
CEO Paul Hudson came to Sanofi's capital markets day with big news and key messages for investors about the company's future business model.
Sanofi Has The Fire Power For Deals, CEO Hudson Says
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.
Sanofi, Long-Time Leader In Diabetes, Is Exiting Diabetes Research
The company's decision to exit diabetes research is not necessarily surprising given the development and commercial challenges in the therapeutic area, but it's not insignificant either.
Merck & Co. Joins Competitive BTK Research Space With $2.7bn ArQule Buy
ArQule's lead candidate, ARQ 531, is a novel BTK inhibitor in Phase II development that could work in patients with B-cell malignancies resistant to existing BTK inhibitors like Imbruvica.
Pfizer's Bourla: "I Think We Forgot What It Looks Like To Grow"
The big pharma CEO reflected on his first year of leadership at Pfizer during the Forbes Healthcare Summit and talked about executing on a plan to deliver 6% growth through 2026.
Ardelyx Plans Mid-2020 NDA Filing For Tenapanor In Hyperphosphatemia
The company reported positive Phase III data from a second trial testing the first-in-class therapy as monotherapy for managing hyperphosphatemia in patients on dialysis.